Tokyo, Japan, Dec. 06, 2006 - (JCN Newswire) - Takeda Pharmaceutical Company Limited today announced that it will launch, on December 7, "Takepron(R) I.V. for Injection 30mg" (generic name: lansoprazole) in Japan which is a treatment for peptic ulcer as an additional dosage formulation to the current oral ones.
Lansoprazole is a proton pump inhibitor discovered and developed by Takeda, and the newly launched injectable formulation was approved for bleeding associated with gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion for the patients who are not able to take the drug orally. The approved dosage and administration is 30mg twice a day.
"Takepron(R) has evidenced efficacy for suppression of gastric acid secretion from the parietal cell," said Makoto Yamaoka, Senior Managing Director, General Manager of Pharmaceutical Marketing Division of Takeda. "With the addition of the injectable formulation, we believe the product line of Takepron(R) will be further contributing to treatment of patients with peptic ulcers since Takepron(R) has been approved for a variety of indications while it is available in the administration/treatment options such as orally disintegrating tablets that can be taken without water, and the product in one package with other medications for eradication of Helicobactor pylori."
About Takepron(R) I.V. for Injection 30mg
Indications: The following indications for patients who are unable to take the oral formulations; gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion accompanied with bleeding
Posology: For adults, usually Takepron I.V. for Injection 30mg can be Injection, JP and administered by intravenous drip infusion twice a day. Or Takepron I.V. for Injection 30mg can be reconstituted into 20ml of Saline Solution, JP or 5% Dextrose Injection, JP and be gradually administered by intravenous infusion twice a day. 1. As Takepron I.V. for Injection can show high hemostatic effect with three-days treatment, once the patient is able to take medications orally, therapy should be switched to an oral formulation and this drug should not be administered aimlessly for a long period. 2. There is no clinical experience over 7 days treatment in Japanese clinical trials
Registration: Approved on October 20, 2006
NHI Price: Yen 634.00 (including tax), listed on December 1, 2006
About Takeda Pharmaceutical Takeda Pharmaceutical, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com/index-e.html.
Contact
Takeda Pharmaceutical Shouji Wakayama Wakayama_Shouji@takeda.co.jp +81-6-6204-2111
